 SAN DIEGO, Oct. 13, 2021 GLOBE NEWSWIRE -- TRACON Pharmaceuticals NASDAQ:TCON, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Carol Lam to its Board of Directors. 